Why UK GLP-1 pages tell you so much less

The rule that explains the difference

Rule 12.12 of the CAP Code is one sentence: “Prescription-only medicines or prescription-only medical treatments may not be advertised to the public.” It is not a guideline about tone. It rules out most of what an American weight-loss page consists of.

The ASA’s own advice spells out how far that reaches. A UK advertiser may not name the drug, and may not use the workarounds either — “weight loss injections”, “weight loss pen”, “skinny jab”, “obesity treatment jab”, or the class name “GLP-1”. It may not show an injection pen, branded or not, or a vial. It may not run before-and-after photographs, celebrity endorsements or endorsements from health professionals. It may not say “once-a-week weight loss treatment”. And it may not print a price against any of it: the ASA gives “from £139.50 per pen” as an example of what is not allowed.

What is left is narrow. A pharmacy may advertise a consultation for weight loss, provided the ad does not indicate that the likely outcome will be a prescription for a prescription-only medicine. That is the whole permitted pitch.

What the ASA has actually done

This is enforced rather than merely written down. On 9 July 2025 the ASA published rulings against nine advertisers, predominantly pharmacies, and issued a joint Enforcement Notice to all 13,214 pharmacies on the General Pharmaceutical Council register — which is to say, to the entire sector at once rather than to the offenders.

It also monitors by machine. Between February and June 2025 the ASA’s Active Ad Monitoring system captured more than 20,000 ads from 35 high-priority pharmacies and found 80 that named a drug directly. The ASA reports that as roughly 99% compliance, which is a reasonable way to read it — and also means the scanning is continuous rather than complaint-led. A UK provider’s marketing is being watched in a way its American counterpart’s simply is not.

The other UK regulator, and what it found

The MHRA polices the medicines themselves rather than the advertising, and its concern is supply outside the pharmacy system. Since January 2023 it has seized 369 potentially falsified Ozempic pens, along with fake Saxenda. The reason that matters is what appears to have been in them: the MHRA reported that “serious side effects reported of those hospitalised, including hypoglycaemic shock and coma, indicate that the pens may contain insulin rather than semaglutide.”

Insulin given to someone who does not need it is not a lesser version of a GLP-1. It is a different drug with a different failure mode, and hypoglycaemic coma is that failure mode. The agency repeated the warning on 29 December 2025, ahead of the New Year market it clearly expects: “Products sold illegally may be fake, contaminated, incorrectly dosed, or contain powerful ingredients not listed on the packaging.”

How to read a UK provider, given all that

• ◆A vague homepage is expected and is not itself a warning sign. The price and the drug name usually appear only after you have started a consultation, because that is where the rules permit them.
• ◆Check the pharmacy on the GPhC register before you check anything else. It is the one step that separates a regulated supplier from everything else, and it takes a minute.
• ◆Judge a UK provider on what the rules still let it publish: who assesses you and whether they are named, whether a pharmacist reviews the case, cancellation terms, what happens to unused supply, and whether it will write to your GP.
• ◆Treat any UK site that names the drug in its advertising as having told you something about how it handles rules generally — the ASA has published rulings on exactly that.
• ◆A site that sells without a consultation is not a cheaper option. On the MHRA’s evidence it is the category that has put people in hospital.

The route that is not a private clinic

NICE has appraised tirzepatide for managing overweight and obesity in TA1026, and NHS England is rolling out weight-management injections against criteria set centrally rather than by whoever you buy from. The NHS route is slower and its eligibility is narrower than any private clinic’s, and for many people it will not be available yet. But it costs a prescription charge rather than a monthly subscription, and it is worth checking your position against the current criteria before assuming private is the only option.